Endocyte, Inc. (ECYT) Expected to Post Earnings of -$0.16 Per Share

Brokerages expect Endocyte, Inc. (NASDAQ:ECYT) to post earnings of ($0.16) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Endocyte’s earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.15). Endocyte reported earnings per share of ($0.26) during the same quarter last year, which suggests a positive year-over-year growth rate of 38.5%. The firm is expected to report its next earnings report on Friday, March 9th.

On average, analysts expect that Endocyte will report full-year earnings of ($1.24) per share for the current year, with EPS estimates ranging from ($1.25) to ($1.23). For the next year, analysts expect that the business will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Endocyte.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The business had revenue of $0.03 million during the quarter. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. The company’s revenue for the quarter was up .0% compared to the same quarter last year.

ECYT has been the topic of several research analyst reports. ValuEngine raised Endocyte from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $2.00 to $7.00 in a report on Tuesday, October 3rd. Cowen reissued a “hold” rating on shares of Endocyte in a report on Monday, October 2nd. Finally, Zacks Investment Research raised Endocyte from a “sell” rating to a “hold” rating in a report on Thursday, November 9th.

Shares of Endocyte (ECYT) traded up $0.03 on Tuesday, reaching $3.98. The company’s stock had a trading volume of 306,500 shares, compared to its average volume of 399,593. Endocyte has a one year low of $1.17 and a one year high of $6.55. The firm has a market capitalization of $169.45, a price-to-earnings ratio of -2.95 and a beta of 2.20.

In other news, VP Christopher P. Leamon sold 23,231 shares of Endocyte stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $5.04, for a total value of $117,084.24. Following the sale, the vice president now directly owns 150,579 shares of the company’s stock, valued at $758,918.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Philip S. Low sold 50,511 shares of Endocyte stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $4.41, for a total value of $222,753.51. The disclosure for this sale can be found here. Insiders sold 124,253 shares of company stock worth $562,591 over the last ninety days. Corporate insiders own 14.86% of the company’s stock.

Several large investors have recently modified their holdings of the company. FMR LLC boosted its stake in shares of Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock worth $5,310,000 after acquiring an additional 31,168 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Endocyte by 1,064.3% in the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after acquiring an additional 393,975 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 25,003 shares during the last quarter. 17.45% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/23/endocyte-inc-ecyt-expected-to-post-earnings-of-0-16-per-share.html.

About Endocyte

Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Get a free copy of the Zacks research report on Endocyte (ECYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply